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A B S T R A C T
Antibiotic resistance carries a fitness cost that could potentially limit the spread of resistance in
bacterial pathogens. In spite of this cost, a large number of experimental evolution studies have found
that resistance is stably maintained in the absence of antibiotics as a result of compensatory evolution.
Clinical studies, on the other hand, have found that resistance in pathogen populations usually declines
after antibiotic use is stopped, suggesting that compensatory adaptation is not effective in vivo. In this
article, we argue that this disagreement arises because there are limits to compensatory adaptation in
nature that are not captured by the design of current laboratory selection experiments. First, clinical
treatment fails to eradicate antibiotic-sensitive strains, and competition between sensitive and resistant
strains leads to the rapid loss of resistance following treatment. Second, laboratory studies overestimate
the efficacy of compensatory adaptation in nature by failing to capture costs associated with compen-
satory mutations. Taken together, these ideas can potentially reconcile evolutionary theory with the
clinical dynamics of antibiotic resistance and guide the development of strategies for containing resist-
ance in clinical pathogens.
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COMPENSATORY ADAPTATION AND
THE MAINTENANCE OF ANTIBIOTIC
RESISTANCE
Evolving antibiotic resistance by horizontal gene
transfer or by chromosomal mutation is associated
with a fitness cost, as demonstrated by the fact that
resistant bacteria have reduced growth rates and
competitive ability relative to sensitive strains in
the absence of antibiotics [1–5]. Because resistance
carries a cost, stopping antibiotic use once resist-
ance begins to spread in a bacterial population
should provide a simple and effective strategy for
preventing the emergence of resistance [5–9]. In a
classic experiment, Schrag and Perrot [10] tested this
idea by allowing populations founded by strepto-
mycin-resistant clones of Escherichia coli to evolve
in the absence of antibiotics. Contrary to their ex-
pectations, they found that resistance was stably
maintained in the absence of antibiotics because
resistant clones adapted to the cost of resistance
by evolving second-site compensatory mutations
that recovered the cost of resistance [11]. A large
number of studies have now used the same basic
experimental design developed by Schrag et al. to
study how bacteria adapt to the cost of resistance
(reviewed in Ref. 2). They have utilized a wide range
of study organisms, including major human patho-
gens such as Mycobacterium tuberculosis,
Staphylococcus aureus, E. coli, Streptococcus
pneumoniae and Pseudomonas aeruginosa. These
studies have also used a variety of antibiotics from
at least eight different antibiotic classes, as well as
several mobile genetic elements (MGEs) that carry
antibiotic resistance genes. These studies have re-
ported that resistance, regardless of species or anti-
biotic, is almost always maintained in the absence of
antibiotics as a result of compensatory adaptation
[2, 4, 12].
The best evidence for compensatory adaptation in
natural populations comes from studies that have
found evidence for known compensatory adapta-
tions in clinical isolates. For example, an early study
by Nagaev et al. [13] found that clinical fusidic acid-
resistant strains of S.aureus carry mutations in do-
mains of EF-G that have shown to be involved in
compensatory adaptation in the laboratory. More
recently, targeted and whole-genome sequencing
of clinical isolates has shown that adaptation to
the cost of rifampicin resistance has occurred in iso-
lates of M.tuberculosis [14–16]. However, despite the
chronic nature of tuberculosis (TB) infections and
high rates of person-to-person transmission, these
studies have found compensation in a minority of
cases—approximately 30% of global drug-resistant
isolates. Although these elegant studies clearly show
that compensatory adaptation is possible in natural
pathogen populations, they do not provide any gen-
eral insights into the prevalence of compensatory
adaptation.
If compensatory adaptation is commonplace in
clinical bacterial pathogens, then resistance should
be maintained after antibiotic use is discontinued.
A simple way to test for the maintenance of antibi-
otic resistance is to measure the prevalence of re-
sistant isolates in samples taken from patients
before and after exposure to antibiotics relative
to suitable controls. A recent meta-analysis of this
type of study performed on community infections
concluded that the frequency of resistant isolates
increases following antibiotic treatment, and then
slowly returns to towards the baseline level [17].
For example, the frequency of macrolide resistance
in streptococci rapidly increased following treat-
ment with azythromicin or clarithromycin, but resist-
ance declined back to near baseline levels by 12
months post-treatment [18]. More dramatically, b-
lactam resistance in the Haemophilus populations
of children who were treated with amoxicillin
declined back to baseline levels within 12 weeks [19].
At a broader scale, it has been shown that resist-
ance follows repeatable seasonal fluctuations that
lag behind antibiotic prescription rates [20, 21]. For
example, prescriptions for antibiotics in the US peak
in the winter and then decline towards a low in the
summer. Resistance also follows this pattern, but
with a lag. These seasonal cycles are repeated across
years, so that the frequency of resistance towards
commonly used antibiotics remains relatively con-
stant [20]. Clearly, this pattern is not what you would
expect if compensation was rampant. It is important
to note that reducing antibiotic consumption does
not necessarily result in reduced antibiotic resist-
ance. For example, large-scale reductions in the
use of sulphonamide and trimethoprim to treat
E.coli infections at a regional or national scale had
little or no impact on the frequency of antibiotic re-
sistance [22, 23]. In both of these cases, resistance
did not carry a cost in the laboratory [23, 24], raising
the possibility that these interventions may have
failed in part because of the fact that compensatory
adaptation had removed the cost of resistance prior
to reductions in antibiotic use. However, genotypes
carrying sulphonamide and trimethoprim resistance
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determinants tended to also be resistant to the anti-
biotics that were used to treat E.coli infections once
the use of sulphonamide and trimethoprim were
discontinued. Therefore, the role of compensatory
adaptation in these interventions remains specula-
tive. More generally, a recent meta-analysis of more
than 100 studies examining spatial and temporal
associations between antibiotic resistance and con-
sumption concluded that there was a strong associ-
ation between consumption and resistance [25].
If compensatory adaptation is common, then resist-
ance should be only weakly coupled to consumption
level, and the strong association that exits between
consumption and resistance therefore provides sup-
port for the idea that compensatory adaptation is
rare in clinical settings.
A second way to test for compensatory adaptation
in clinical settings is to compare the fitness of co-
occurring isolates that are antibiotic sensitive and
resistant. Given that resistance carries a cost, sensi-
tive and resistant isolates should tend to have equal
fitness if compensatory adaptation is widespread.
To test this, we searched the published literature
for studies which had compared the fitness of co-
occurring susceptible and resistant clinical isolates
from the same species. Fitness could be measured
by either direct competition experiments, where iso-
lates are co-cultured, or by indirect methods, such as
comparisons of maximum growth rate in mono-
cultures. Studies that have used this approach have
usually found that resistant isolates have a lower
average fitness than sensitive isolates (Box 1
[26–38]). For example, this approach has shown that
methicillin-resistant isolates of S.aureus (MRSA)
from the first MRSA epidemic in Northern Europe
had lower fitness than methicillin-sensitive strains,
and this could explain why MRSA rapidly declined
when methicillin use was reduced [39]. It is import-
ant to emphasize that these studies are associated
with several caveats. For example, these studies do
not control for genetic background and fitness is
measured in the laboratory, rather than in a natural
environments. Nonetheless, these studies clearly
support the idea that compensatory adaptation is
unable to maintain resistance in clinical settings.
In summary, laboratory studies find that bacteria
have the ability to adapt to the cost of antibiotic re-
sistance by compensatory mutation, suggesting that
resistance should be maintained in the absence of
antibiotics. Clinical studies, on the other hand, find
that resistance usually declines when antibiotic use
is stopped or discontinued, and resistant strains
usually have lower fitness than conspecific-sensitive
strains. These results suggest that selection for com-
pensatory adaptation is not able to stabilize resist-
ance in natural populations of pathogenic bacteria.
LIMITS TO COMPENSATORY
ADAPTATION
Sensitive strains survive antibiotic treatment
One feature of laboratory studies of compensatory
adaptation is that selection lines are always initiated
with a single, antibiotic-resistant clone. In most of
these experiments, resistance is caused by a single
chromosomal mutation, and it is highly improbable
that resistance will revert using this experimental
design because of the rarity of reversion mutations.
Single base pair substitutions in bacteria arise at a
rate of approximately 1010 to 1011 per genome per
generation [40], implying that even large bacterial
populations will have to wait a very long time before
reversion mutations occur. For example, in a popu-
lation of 106 cells a reversion mutation is only ex-
pected to occur once every 10 000 generations.
Moreover, the majority of reversion mutations will
be lost due to genetic drift when they are rare, even if
resistance carries a large cost [41]. Given these sim-
ple considerations, it is remarkable that some
studies have found evidence for the loss of resist-
ance as a result of the spread of de novo reversion
mutations [13, 42–44]. The reversion of resistance is
also unlikely in populations initiated with clones
carrying plasmid-borne resistance genes. Plasmids
can be spontaneously lost at cell division, potentially
generating a source of antibiotic-sensitive revert-
ants. However, many plasmids possess high-fidelity
partitioning mechanisms that ensure even segrega-
tion of plasmids at cell division and post-segrega-
tional killing mechanisms which efficiently eliminate
cells lacking plasmids [45]. Consequently, although
estimates of the rate of segregational loss of plas-
mids are lacking, it is generally accepted that the
effective rate of segregational loss of most plasmids
is very low. The horizontal transfer of plasmids by
conjugation may also help to maintain resistance in
the absence of selection. In populations of bacteria
carrying conjugative plasmids, cells that lose plas-
mids by segregational loss risk being re-infected
with plasmids by conjugation, and conjugation
could theoretically allow costly plasmids to persist
indefinitely [46].
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By initiating populations with a single-resistant
clone, experimental evolution studies of compensa-
tion effectively assume that antibiotic treatment
eliminates all antibiotic-sensitive cells a population.
In natural populations this assumption is unlikely to
hold. First, there is heterogeneity in antibiotic expos-
ure within patients and this heterogeneity is likely to
generate refuges containing relatively low doses of
antibiotic [48]. Second, there is heterogeneity in anti-
biotic sensitivity between genetically identical cells
of ‘sensitive’ strains. The classic example of this het-
erogeneity is persister cells: a small fraction of cells
in sensitive strains which are completely refractory
to even very high doses of antibiotics because they
are metabolically dormant [49, 50]. Recent work has
shown that phenotypic heterogeneity in clonal bac-
terial populations extends far beyond persistence
[51–53]. For example, variation in the expression of
genes implicated in resistance ensures that some
cells in sensitive strains have elevated resistance
[54–56]. We argue that the consequence of variation
in antibiotic exposure coupled to variation in antibi-
otic resistance ensures that a small fraction of cells
that lack mutations or mobile elements conferring
high levels of resistance are likely to survive exposure
to treatment.
Given that resistance carries a cost and that a
small fraction of sensitive cells are likely to survive
treatment with antibiotics, then resistance will only
be able to persist if the resistant population is able to















































































This graph summarizes the results of studies that have compared the fitness of co-occuring resistant and sensitive
isolates in the absence of antibiotics, such that fitness = 1 represents equal competitive ability. Numbers in brackets
represent the number of resistant isolates examined in each study. Fitness was estimated by either direct competition
between sensitive and resistance isolates, or by proxy methods such as comparing rates of exponential growth. Resistant
isolates have reduced competitive ability in 12/13 studies, and this difference is highly significant under a binomial test
(P< 0.001). These studies were identified as part of a systematic meta-analysis of laboratory estimates of the cost of
resistance [47]. However, these studies were not included in the meta-analysis presented in [47], clinical isolates can differ
in more than just the resistant determinant.
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adapt to overcome the cost of resistance before
being displaced by sensitive competitors. To better
understand this process, we used a simple popula-
tion genetic model of competition between a resist-
ant and sensitive strain of bacteria. We assume that
resistance carries a fixed cost, and that the sensitive
strain makes up a non-zero fraction of the bacterial
population after treatment (Fig. 1). The insight of
this model is that resistance is likely to be lost very
quickly, even if only a small fraction of the population
that survives antibiotic treatment is antibiotic sensi-
tive. For example, the average cost of a chromo-
somal resistance mutation is approximately 20%
[47], and the model predicts that an average resist-
ance mutation will be rapidly lost, even if only a small
fraction of the population that survives treatment is
sensitive. The quantitative predictions of this model
need to be taken with a grain of salt; however, be-
cause it ignores the pharmacodynamics of antibiotic
exposure [48] and it also does not consider the pos-
sibility of compensatory adaptation. One important
exception to this argument is that the survival of
sensitive strains is unlikely to constrain compensa-
tion in patients suffering from chronic infections.
Patients suffering from chronic infections, such as
those associated with cystic fibrosis and TB, are
given extended treatments with antibiotics that can
last for months. Under these extreme conditions,
sensitive strains are likely to eradicated, and this
process may help to explain why some of the best
evidence for compensatory adaptation is from
M.tuberculosis [14–16, 57].
Imperfect compensation drives reversion
Compensatory mutations increase the fitness of
resistant strains, but it has often been observed
that compensatory mutations do not completely
recover the cost associated with resistance [11,
43, 58]. We speculate that compensatory muta-
tions provide an imperfect solution to the cost
of resistance because compensatory mutations
are associated with costs of their own. In support
of this idea, compensatory mutations are often
found in essential genes [2, 59], and it is well es-
tablished that compensatory mutations are costly
in the absence of resistance mutations [11, 43,
58]. The fact that compensation is imperfect is
unlikely to matter in standard laboratory selection
experiments, as strains carrying compensatory
mutations will still have a fitness advantage rela-
tive to their resistant competitors. There is also
some evidence to suggest that compensatory mu-
tations are less effective at recovering the cost of
resistance under natural conditions than under la-
boratory conditions. Bjorkman et al. [43] found
that compensation was less likely for fusidic acid
resistance in Salmonella typhymurium when
passaged through a mouse as opposed to labora-
tory media. Crucially, all compensatory mutations,
whether selected in vitro or in vivo, were more ef-
fective at restoring fitness in vitro than in vivo. It
therefore appears that even when compensatory
mutations fully restore laboratory fitness, this
compensation is environment specific and there-
fore may not be as effective in clinical
Frequency of sensive strain in populaon following 
treatment



















) 0.95 269 224 180 135 90
0.9 131 109 87 66 44
0.85 85 71 57 43 28
0.8 62 52 41 31 21
0.75 48 40 32 24 16
Figure 1. Half-life of resistance following antibiotic treatment This figure shows the expected half-life (measured in number of
generations) of an antibiotic resistant strain (R) in competition with a higher fitness antibiotic sensitive strain (S) following
antibiotic treatment. The key prediction of the model is that resistance should be rapidly eliminated in the absence of antibiotics,
provided that sensitive strains make up a small fraction of the population that survives treatment. Half-life was calculated from
log (St/Rt) = log (S0/R0) + t log (w) where t is time and w is the relative fitness of the resistant strain. We assume that half-life is the
time taken for the resistant strain to decline to a frequency of 0.5.
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environments. Unfortunately, this study was not
able to determine why compensatory mutations
were unable to effectively restore fitness in vivo,
and it is therefore unclear to what extent the re-
sults of this study are generally applicable to anti-
biotic resistance. Future experimental work should
focus on measuring the fitness effects of compen-
satory mutations in vivo, and determining how en-
vironmental and genetic variation influence the
benefits associated with compensatory adaptation.
CONCLUSION
In an influential article published in 2010,
Andersson and Hughes [2] argued that the condi-
tions favouring the loss of established resistance
genes in populations of pathogenic bacteria are
likely to be very restrictive. Although there are
some elegant examples of compensatory adapta-
tion in clinical pathogens that support this view
[13, 14, 16, 60–62], recent clinical studies show
that resistance is usually lost in pathogen popu-
lations once antibiotic resistance is reduced or
stopped. In contrast, laboratory experiments have
almost always found that resistance is maintained
in the absence of antibiotics. In this article, we
argue that this discrepancy arises because there
are limits to compensatory adaptation in nature
that are not captured by the design of current
laboratory selection experiments. In clinical
settings, there is good empirical evidence that
antibiotic treatment will often fail to eradicate
‘sensitive’ bacteria, and there are good theoretical
reasons for thinking that surviving antibiotic-sen-
sitive strains should rapidly replace resistant
strains that are inferior competitors. In contrast,
laboratory experiments favour compensatory
adaptation, because compensatory mutations
carry large benefits in the laboratory, and the de-
sign of laboratory experiments protects resistant
clones carrying compensatory mutations from
competition with high fitness antibiotic-sensitive
clones.
Antibiotic resistance has been demonstrated to
carry a fitness cost, both in vitro and in vivo [2].
However our understanding of the importance of
compensatory adaptation in mitigating this cost
in vivo remains fragmentary because of a lack of
synergy in the approaches used to study the main-
tenance of resistance. Experimental evolution
studies provide detailed insights into the
dynamics and mechanisms of compensatory
adaptation, but under conditions that lack several
key features of the natural biological context in
which resistance evolves. For example, experimen-
tal evolution studies have focused on using model
systems involving a single chromosomal resist-
ance mutation, whereas antibiotic-resistant clin-
ical isolates usually carry multiple resistance
mutations or MGEs that provide resistance
against a broad spectrum of antimicrobials.
Experimental evolution studies should place a
greater emphasis on studying clinically relevant
resistance mechanisms, and it would be especially
interesting to see future work on resistance genes
that pose the most important threats to human
health, such as MGEs carrying carbapenem resist-
ance genes [63–65]. On average, MGEs carry a
smaller fitness costs than chromosomal resist-
ance mutations, and this may help to explain
why mobile elements have played such an import-
ant role in the evolution of resistance in human
pathogens [65–68]. Experimental evolution studies
have shown that compensatory adaptation can
eliminate the cost of MGEs [69–71], but it is un-
clear if it is easier to evolve compensatory adap-
tations for MGEs than chromosomal mutations.
When resistance evolves by MGE acquisition,
compensatory adaptations can occur on both
the chromosome and on the MGE [69], and this
may accelerate compensatory adaptation. An im-
portant assumption of this argument is that com-
pensation benefits both bacteria and their MGEs,
which is likely to be the case for mobile elements
that have predominantly vertical transmission,
such as non-mobilizable plasmids and integrative
and conjugative elements (ICEs). It is more diffi-
cult to predict the impact of compensatory adap-
tation on the fitness of MGEs with a high rate of
horizontal transmission, such as conjugative plas-
mids and lysogenic bacteriophages. For example,
trade-offs in the cost imposed by MGEs on alter-
native hosts may restrict the evolution of compen-
satory adaptations that improve fitness on a
single host.
Another important difference between experimen-
tal evolution studies and clinical settings comes
from bacteria that are used as model organisms.
Experimental evolution studies tend to use well-
characterized strains of important pathogens, such
as E.coli, S.aureus and M.tuberculosis. These strains
are usually highly domesticated, and can differ sub-
stantially from the dominant clones of these bacteria
that cause infections in clinical settings. It is unclear
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to what extent the use of model strains has biased
the outcome of laboratory studies, but a recent study
that measured the cost of rifampicin resistance
across strains of Pseudomonas shows that genetic
background plays a dominant role in determining
the cost of resistance [72]. Although the mechanistic
basis of this ‘background effect’ remains unclear,
these results imply that caution must be used when
extrapolating fitness measures of resistance in lab
strains to clinical strains.
Clinical studies, on the other hand, have focused
on documenting the dynamics of resistance without
providing insight into the mechanisms that drive
these patterns. For example, it is clear that resist-
ance tends to decline in individual patients following
antibiotic use. However it is unclear if these declines
are caused by the reversion of resistance, the immi-
gration of competitively superior antibiotic-sensitive
strains, or by the spread of antibiotic-sensitive sur-
vivors of treatment. Whole-genome sequencing
(WGS) of clinical isolates has started to provide in-
valuable insights into the evolution of pathogenic
bacteria on a clinically relevant timescale [73–78],
and large-scale sequencing of longitudinal samples
of clinical isolates will provide a much more detailed
view of the dynamics of resistance evolution. We
suggest that it may be difficult to understand the
significance of changes in the genetic structure of
bacterial populations revealed by WGS unless
sequencing is accompanied by phenotypic measure-
ments of relevant traits, such as antibiotic resistance
and competitive ability, which are commonly used in
experimental evolution studies.
In summary, we think that progress in our under-
standing of the forces maintaining antibiotic resist-
ance in pathogen populations will be best achieved
using a combination of approaches from clinical
microbiology and experimental evolution. It is im-
portant that we make progress in this area, because
an increased understanding of the evolutionary
processes that maintain resistance can be used to
inform clinical usage of antibiotics. Much of the cur-
rent effort in fighting antibiotic resistance is
focussed on limiting antibiotic use via reduced pre-
scriptions. If compensatory adaptation is highly per-
vasive, reducing antibiotic consumption is unlikely
to drastically curtail antibiotic resistance. However
we argue that compensatory adaptation is less
prevalent in clinical real-world populations than pre-
viously thought, and therefore campaigns to reduce
antibiotic usage should remain a major strategy for
preventing antibiotic resistance.
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biological principles of drug-resistance evolution in infec-
tious diseases. Lancet Infect Dis 2011;11:236–47.
8. zur Wiesch PS, Engelstaedter J, Bonhoeffer S.
Compensation of fitness costs and reversibility of antibi-
otic resistance mutations. Antimicrob Agents Chemother
2010;54:2085–95.
9. Tanaka MM, Valckenborgh F. Escaping an evolutionary
lobster trap: drug resistance and compensatory mutation
in a fluctuating environment. Evolution 2011;65:1376–87.
10. Schrag SJ, Perrot V. Reducing antibiotic resistance. Nature
1996;381:120–1.
11. Schrag SJ, Perrot V, Levin BR. Adaptation to the fitness
costs of antibiotic resistance in Escherichia coli. Proc R
Soc B Biol Sci 1997;264:1287–91.
12. Maisnier-Patin S, Berg OG, Liljas L et al.
Compensatory adaptation to the deleterious effect of anti-
biotic resistance in Salmonella typhimurium. Mol Microbiol
2002;46:355–66.
13. Nagaev I, Bjorkman J, Andersson DI et al. Biological cost
and compensatory evolution in fusidic acid-resistant
Staphylococcus aureus. Mol Microbiol 2001;40:433–9.
14. Comas I, Borrell S, Roetzer A et al. Whole-genome
sequencing of rifampicin-resistant Mycobacterium tuber-
culosis strains identifies compensatory mutations in RNA
polymerase genes. Nat Genet 2012;44:106–10.








niversity of Aberdeen user on 02 April 2020
15. Farhat MR, Shapiro BJ, Kieser KJ et al. Genomic analysis
identifies targets of convergent positive selection in drug-
resistant Mycobacterium tuberculosis. Nat Genet 2013;45:
1183–9.
16. de Vos M, Mueller B, Borrell S et al. Putative compensatory
mutations in the rpoC gene of rifampin-resistant
Mycobacterium tuberculosis are associated with ongoing
transmission. Antimicrob Agents Chemother 2013;57:
827–32.
17. Costelloe C, Metcalfe C, Lovering A et al. Effect of antibiotic
prescribing in primary care on antimicrobial resistance in
individual patients: systematic review and meta-analysis.
Br Med J 2010;340:c2096.
18. Malhotra-Kumar S, Lammens C, Coenen S et al. Effect of
azithromycin and clarithromycin therapy on pharyngeal
carriage of macrolide-resistant streptococci in healthy vol-
unteers: a randomised, double-blind, placebo-controlled
study. Lancet 2007;369:482–90.
19. Chung A, Perera R, Brueggemann AB et al. Effect of anti-
biotic prescribing on antibiotic resistance in individual
children in primary care: prospective cohort study. Br
Med J 2007;335:429.
20. Sun L, Klein EY, Laxminarayan R. Seasonality and temporal
correlation between community antibiotic use and resist-
ance in the United States. Clin Infect Dis 2012.
21. Dagan R, Barkai G, Givon-Lavi N et al. Seasonality of anti-
biotic-resistant Streptococcus pneumoniae that causes
acute otitis media: a clue for an antibiotic-restriction pol-
icy? J Infect Dis 2008;197:1094–102.
22. Enne VI, Livermore DM, Stephens P et al. Persistence of
sulphonamide resistance in Escherichia coli in the UK des-
pite national prescribing restriction. Lancet 2001;357:
1325–8.
23. Sundqvist M, Geli P, Andersson DI et al. Little evidence for
reversibility of trimethoprim resistance after a drastic re-
duction in trimethoprim use. J Antimicrob Chemother
2010;65:350–60.
24. Enne VI, Bennett PM, Livermore DM et al. Enhancement of
host fitness by the sul2-coding plasmid p9123 in the ab-
sence of selective pressure. J Antimicrob Chemother 2004;
53:958–63.
25. Bell BG, Schellevis F, Stobberingh E et al. A systematic
review and meta-analysis of the effects of antibiotic
consumption on antibiotic resistance. BMC Infect Dis
2014;14:13.
26. Abdelraouf K, Kabbara S, Ledesma KR et al. Effect of
multidrug resistance-conferring mutations on the fitness
and virulence of Pseudomonas aeruginosa. J Antimicrob
Chemother 2011;66:1311–7.
27. Bhatter P, Chatterjee A, D’Souza D et al. Estimating
fitness by competition assays between drug suscep-
tible and resistant Mycobacterium tuberculosis of pre-
dominant lineages in Mumbai, India. PLoS One
2012;7:e33507.
28. Corich L, Dolzani L, Tonin EA et al. Metallo-Beta-
Lactamase expression confers an advantage to
Pseudomonas aeruginosa isolates compared with other
Beta-Lactam resistance mechanisms, favoring the preva-
lence of Metallo-Beta-Lactamase producers in a clinical
environment. Microb. Drug Resist 2010;16, 223–30.
29. Davies AP, Billington OJ, Bannister BA et al. Comparison
of fitness of two isolates of Mycobacterium tuberculosis, one
of which had developed multi-drug resistance during the
course of treatment. J Infect 2000;41:184–7.
30. Foucault M-L, Courvalin P, Grillot-Courvalin C. Fitness
cost of VanA-type vancomycin resistance in methicillin-
resistant Staphylococcus aureus. Antimicrob Agents
Chemother 2009;53:2354–9.
31. Gagneux S, Long CD, Small PM et al. The competitive cost
of antibiotic resistance in Mycobacterium tuberculosis.
Science 2006;312:1944–6.
32. Gillespie SH, Billington OJ, Breathnach A, McHugh TD.
Multiple drug-resistant Mycobacterium tuberculosis: evi-
dence for changing fitness following passage through
human hosts. Microb Drug Resist 2002;8:2739.
33. Nielsen KL, Pedersen TM, Udekwu KI et al. Fitness cost: a
bacteriological explanation for the demise of the first inter-
national methicillin-resistant Staphylococcus aureus epi-
demic. J Antimicrob Chemother 2012;67:1325–32.
34. O’Sullivan DM, McHugh TD, Gillespie SH. Mapping the
fitness of Mycobacterium tuberculosis strains: a omplex pic-
ture. J Med Microbiol 2010;59:1533–5.
35. Sandegren L, Lindqvist A, Kahlmeter G, Andersson DI.
Nitrofurantoin resistance mechanism and fitness cost in
Escherichia coli. J Antimicrob Chemoth 2008;62:495–503.
36. Shorten RJ, McGregor AC, Platt S et al. When is an out-
break not an outbreak? Fit, divergent strains of
Mycobacterium tuberculosis display independent evolution
of drug resistance in a large London outbreak. J Antimicrob
Chemother 2013;68:543–9.
37. Sun Z, Jiao X, Peng Q et al. Antibiotic resistance in
Pseudomonas aeruginosa is associated with decreased fit-
ness. Cell Physiol Biochem 2013;31:347–54.
38. von Groll A, Martin A, Stehr M et al. Fitness of
Mycobacterium tuberculosis strains of the W-Beijing and
non-W-Beijing genotype. PLoS One 2010;5:e10191.
39. Nielsen KL, Pedersen TM, Udekwu KI et al. Fitness
cost: a bacteriological explanation for the demise of
the first international methicillin-resistant Staphylococcus
aureus epidemic. J Antimicrob Chemother 2012;67:
1325–32.
40. Wielgoss S, Barrick JE, Tenaillon O et al. Mutation rate
inferred from synonymous substitutions in a long-term
evolution experiment with Escherichia coli. G3 2011;1:
183–6.
41. Gifford DR, MacLean RC. Evolutionary reversals of
antibtioic resistance in experimental populations of
Pseudomonas aeruginosa. Evolution 2013;67:2973–81.
42. Hall AR, Griffiths VF, MacLean RC et al. Mutational neigh-
bourhood and mutation supply rate constrain adaptation
in Pseudomonas aeruginosa. Proc R Soc Lond B Biol Sci
2010;277:643–50.








niversity of Aberdeen user on 02 April 2020
43. Bjorkman J, Nagaev I, Berg OG et al. Effects of environ-
ment on compensatory mutations to ameliorate costs of
antibiotic resistance. Science 2000;287:1479–82.
44. Meka VG, Gold HS, Cooke A et al. Reversion tosusceptibility
in a linezolid-resistant clinical isolate of Staphylococcus aur-
eus. J Antimicrob Chemother 2004;54:818–20.
45. Phillips G, Funnell B. Plasmid Biology. Washington, D.C:
ASM Press, 2004.
46. Smith J. The social evolution of bacterial pathogenesis.
Proc R Soc Lond Biol Sci 2001;268:61–9.
47. Vogwill T, MacLean RC. The genetic basis of the fitness
cost of antimicrobial resistance: a meta-anlysis approach.
Evol Appl. 2015; (in press).
48. Drusano GL. Antimicrobial pharmacodynamics: critical
interactions of ‘bug and drug’. Nat Rev Microbiol 2004;2:
289–300.
49. Balaban NQ. Persistence: mechanisms for triggering and
enhancing phenotypic variability. Curr Opin Genet Dev
2011;21:768–75.
50. Balaban NQ, Merrin J, Chait R et al. Bacterial persistence
as a phenotypic switch. Science 2004;305:1622–5.
51. Javid B, Sorrentino F, Toosky M et al. Mycobacterial mis-
translation is necessary and sufficient for rifampicin
phenotypic resistance. Proc Natl Acad Sci U S A 2014;
111:1132–7.
52. Silander OK, Nikolic N, Zaslaver A et al. A genome-wide
analysis of promoter-mediated phenotypic noise in
Escherichia coli. PLoS Genet 2012;8:e1002443.
53. Avery SV. Microbial cell individuality and the underlying
sources of heterogeneity. Nat Rev Microbiol 2006;4:577–87.
54. Sánchez-Romero MA, Casadesús J. Contribution of
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